AbbVie Inc (ABBV)vsOwlet Inc (OWLT)
ABBV
AbbVie Inc
$291.31
+1.07%
HEALTHCARE · Cap: $521.11B
OWLT
Owlet Inc
$4.17
-1.65%
HEALTHCARE · Cap: $121.85M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 57599% more annual revenue ($66.01B vs $114.41M). ABBV leads profitability with a 15.7% profit margin vs -8.4%. ABBV earns a higher WallStSmart Score of 77/100 (B+).
ABBV
Strong Buy77
out of 100
Grade: B+
OWLT
Hold37
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-85.2%
Fair Value
$157.29
Current Price
$291.31
$134.02 premium
Intrinsic value data unavailable for OWLT.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 37.2%
Earnings expanding 2282.0% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Conservative balance sheet, low leverage
Revenue surging 29.9% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -526.0% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 15.7% and operating margin at 37.2%. Revenue growth of 10.3% demonstrates continued momentum.
Bull Case : OWLT
The strongest argument for OWLT centers on Debt/Equity, Revenue Growth. Revenue growth of 29.9% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 50.7x leaves little room for execution misses.
Bear Case : OWLT
The primary concerns for OWLT are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
ABBV profiles as a mature stock while OWLT is a growth play — different risk/reward profiles.
OWLT carries more volatility with a beta of 2.22 — expect wider price swings.
OWLT is growing revenue faster at 29.9% — sustainability is the question.
ABBV generates stronger free cash flow (7.3B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (77/100 vs 37/100), backed by strong 15.7% margins and 10.3% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Owlet Inc
HEALTHCARE · MEDICAL DEVICES · USA
Owlet Inc. is a leading innovator in infant health technology, dedicated to enhancing the safety and wellness of newborns through its state-of-the-art monitoring solutions. The company's flagship product, the Owlet Smart Sock, employs advanced pulse oximetry to provide parents with real-time insights into their infants' heart rates and oxygen levels via mobile devices. With growing demand for pediatric health monitoring solutions, Owlet is well-positioned to expand its product offerings and fortify its market presence. The company's focus on delivering actionable health information and improving pediatric care aligns with institutional investors' interests in the dynamic health technology sector.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?